Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147125 | 0.86 | P2RX4 (0.50) | ELANEP2RX4LMNAMAPTHTT | |
| SCHEMBL20138825 | 0.85 | ELANE (0.54) | ELANEMAPTPLAUMEN1KMT2A | |
| SCHEMBL20158841 | 0.83 | ELANE (0.56) | ELANELMNAMAPTMEN1KMT2A | |
| SCHEMBL21330594 | 0.73 | P2RX4 (0.54) | ELANEP2RX4LMNAMAPTHTT | |
| SCHEMBL20135932 | 0.73 | P2RX4 (0.50) | ELANEP2RX4LMNAMAPTHTT | |
| SCHEMBL24200445 | 0.73 | MAPK8 (0.53) | ELANEP2RX4PLAUALDH1A1 | |
| SCHEMBL15113979 | 0.73 | P2RX4 (0.57) | P2RX4LMNAMAPTHTTAGTR1 | |
| SCHEMBL872109 | 0.72 | P2RX4 (0.81) | ELANEP2RX4LMNAMAPTHTT | |
| SCHEMBL20159077 | 0.71 | LMNA (0.55) | ELANELMNAMAPTMEN1KMT2A | |
| SCHEMBL21330598 | 0.69 | P2RX4 (0.53) | P2RX4LMNAMAPTHTTAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538529-B1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2022-01-19 | — | — | EP | disclosed |
| EP-3538529-B1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2022-01-19 | — | — | EP | disclosed |
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2021-06-08 | — | — | US | disclosed |
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2021-06-08 | — | — | US | disclosed |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | US | disclosed |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | US | disclosed |
| WO-2018087389-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| EP-3321264-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
| EP-3321264-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | IKBKB, NFKBIA, IKBKE | ELANE 3681/4885P2RX4 4826/4885LMNA 3293/4885 |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | IKBKB, NFKBIA, IKBKE | ELANE 3684/4885P2RX4 4839/4885LMNA 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.